Dirk Schadendorf
YOU?
Author Swipe
View article: Messages for ultraviolet‐radiation protection to fair‐skinned populations
Messages for ultraviolet‐radiation protection to fair‐skinned populations Open
Background Skin cancer prevention remains a critical public health challenge, particularly in fair‐skinned populations in Europe, the United States and Australia, where incidence rates of keratinocyte skin cancer and melanoma continue to r…
View article: Multiomic profiling of a unique in-transit melanoma cohort identifies melanoma differentiation as predictor of tumor progression and therapy response
Multiomic profiling of a unique in-transit melanoma cohort identifies melanoma differentiation as predictor of tumor progression and therapy response Open
Melanoma patients with in-transit metastasis (ITM), a stage of disease where melanoma has metastasized to sites in between the primary lesion and draining lymph node, vary significantly in their clinical outcomes, but the biology driving d…
View article: Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
CD8 characterization in the TME.
View article: Supplementary Table S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Table S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Changes in immune cell populations in the NIVO + RELA arm from baseline to week 4.
View article: Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
PFS stratified by low or medium LAG-3+/−CD8+ tumors in patients treated with NIVO + RELA compared with NIVO.
View article: Data from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Data from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Purpose:Administration of the lymphocyte activation gene 3 (LAG-3) inhibitor relatlimab (RELA) and the PD-1 inhibitor nivolumab (NIVO) significantly prolonged progression-free survival (PFS) versus NIVO alone in patients with advanced mela…
View article: Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Additional associations of on-treatment changes in CD8+ CM and CD4+ EM cell populations with best overall response.
View article: Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Association between MHC-I or MHC-II and PFS or ORR in patients treated with NIVO + RELA or NIVO.
View article: Supplementary Table S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Table S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Percentage of patients with PD-L1–positive tumors among LAG 3+CD8+ tumor subgroups.
View article: Supplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Characterization of gene expression associated with (A) LAG-3 and (B) PD-L1 expression on immune and tumor cells.
View article: Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Prevalence of (A) LAG-3 and (B) PD-L1 expression by site of collection.
View article: Supplementary Table S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Table S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Representativeness of study participants.
View article: Supplementary Figure S8 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Figure S8 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Characterization of gene signatures in tumor samples associated with treatment arm, NIVO + RELA (A) versus NIVO (B); and type of response, CR/PR (C) versus PD (D).
View article: Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Prevalence of LAG-3+CD8+ subgroups in the NIVO + RELA and NIVO arms.
View article: Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047 Open
Background Treatment-free survival (TFS; time spent free of systemic anticancer therapy) is increasingly used to support traditional endpoints. TFS was previously evaluated in patients with advanced melanoma treated with nivolumab plus ipi…
View article: Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients Open
Type and outcome of systemic therapy differed between cancer entities. Efficacy of ICI was high in PDS and AS, moderate in KS, and low in CAC. Patients with advanced CAC revealed an extremely poor prognosis regardless of the type of therap…
View article: Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG Open
No overall sex-specific survival differences were detected for metastatic melanoma patients in the first-line therapy setting. According to subgroup analyses males show a trend towards a survival advantage over females.
View article: COLUMBUS part 1–7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma
COLUMBUS part 1–7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma Open
This summary presents 7-year results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) (COMBO group), against encorafenib alone (ENCO group), or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment …
View article: Automated ICD-O-3 Coding of Real-World Pathology Reports Using Self-Hosted Large Language Models
Automated ICD-O-3 Coding of Real-World Pathology Reports Using Self-Hosted Large Language Models Open
While large language models (LLMs) have shown promise in medical text processing, their real-world application in self-hosted clinical settings remains underexplored. Here, we evaluated five state-of-the-art self-hosted LLMs for automated …
View article: RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)
RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE) Open
PURPOSE Effective treatment options for melanoma after immune checkpoint blockade failure are limited. RP1 (vusolimogene oderparepvec) is a herpes simplex virus type 1–based oncolytic immunotherapy, here evaluated in combination with nivol…
View article: Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma Open
Neoadjuvant daromun resulted in a significantly longer RFS than upfront surgery in patients with locally advanced melanoma. TRAEs were transient and manageable. Neoadjuvant daromun is a new therapeutic option for patients with stage III me…
View article: Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 Open
Purpose: Administration of the lymphocyte activation gene 3 (LAG-3) inhibitor relatlimab (RELA) and the PD-1 inhibitor nivolumab (NIVO) significantly prolonged progression-free survival (PFS) versus NIVO alone in patients with advanced mel…
View article: Advancing sarcoma diagnostics with expanded DNA methylation-based classification
Advancing sarcoma diagnostics with expanded DNA methylation-based classification Open
Purpose Sarcomas pose a severe diagnostic challenge. A wide variety of these distinct entities need to be distinguished from each other and from less aggressive types of mesenchymal tumors, to ensure correct clinical management. A machine …
View article: Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma Open
We demonstrate a comparable outcome for cemiplimab as second-line treatment of BCC in our real-world patient cohort as reported in previous registration studies. Additionally, we found a trend for a more favorable outcome in first-line the…